Cargando…
Pharmacokinetics of Ceftazidime/Avibactam Following Intravenous Administration in Rabbits: Developing the Preclinical Foundation for Treatment of KPC-Kp Pneumonia in Immunocompromised Patients
BACKGROUND: CRE have been identified by the CDC as one of three urgent antibiotic resistance threats. The international emergence of these pathogens has largely been driven by the dissemination of carbapenemase-producing Klebsiella pneumoniae (KPC-Kp), through enzymes that hydrolyze carbapenems and...
Autores principales: | Petraitis, Vidmantas, Petraitiene, Ruta, Satlin, Michael, Maung, Bo Bo Win, Khan, Farehin, Mazur, Chase, Georgiades, Benjamin, Hayden, Joshua A, Walsh, Thomas J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632020/ http://dx.doi.org/10.1093/ofid/ofx163.660 |
Ejemplares similares
-
In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
por: Huang, Yanqin, et al.
Publicado: (2021) -
Posaconazole Alone and in Combination with Caspofungin for Treatment of Experimental Exserohilum rostratum Meningoencephalitis: Developing New Strategies for Treatment of Phaeohyphomycosis of the Central Nervous System
por: Petraitiene, Ruta, et al.
Publicado: (2020) -
Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment
por: Wang, Lin, et al.
Publicado: (2022) -
706. Ceftazidime-Avibactam (CZA) and Meropenem (MER) Are Synergistic and Bactericidal Against Genetically Diverse KPC-Producing Klebsiella pneumoniae (Kp)
por: Jones, Chelsea, et al.
Publicado: (2018) -
2183. Porin Mutations Potentiate the in Vitro Synergy of Meropenem-Vaborbactam (MVB), but not Ceftazidime-Avibactam (CZA) in Combination with Other Antibiotics against KPC-producing Klebsiella Pneumoniae (KPC-Kp)
por: Rogers, Tara M, et al.
Publicado: (2023)